OM1 Launches Hidradenitis Suppurativa Dataset to Expand Real-World Evidence in Dermatology

New dataset delivers clinical insights on disease staging and treatment effectiveness for accelerating research and improving clinical decision making

BOSTON--(BUSINESS WIRE)--OM1 a leading real-world data, AI and technology company with a focus on chronic diseases, today announced the continued expansion of its Dermatology Network to include Hidradenitis Suppurativa (HS), a systemic inflammatory disease, enhancing the dataset with almost 26,000 patient records.

Studies continue to show the link between skin conditions and mental health. With one in four Americans impacted by a skin disease, combined with the increasing mental health epidemic, it’s critical to uncover and introduce solutions that will ultimately improve health outcomes. What’s more, it’s common for patients with HS, which is associated with multiple somatic and psychiatric comorbidities – including obesity, anxiety, depression and Polycystic Ovary Syndrome – to live with the disease for 12 years or longer before getting diagnosed, as the condition is often misdiagnosed.

“People are going years without an accurate diagnosis of their dermatological conditions, resulting in a worsening of both the disease and the patient’s mental health,” said Stefan Weiss, MD, MBA, FAAD Managing Director of Dermatology at OM1. “Uncovering trends and insights on disease progression to aid in patient identification and treatment personalization is one of the most important steps we can take to improve patient outcomes.”

Leveraging OM1’s augmented, automated, and manual note abstraction capabilities and clinically rich dataset, providers now have access to treatment utilization and machine learning-generated Hurley Stage estimations, the industry’s grading system to classify the extent of HS, across the dataset. Taking advantage of the insights, providers and healthcare stakeholders can more accurately diagnose and stage disease progression in patients to then develop specialized and targeted treatment plans, ultimately allowing them to better care for their patients.

The dataset, which is built off patient records collected over the last decade, includes natural history of disease and patient journeys, treatment effectiveness, phenotypic subtyping, and more, allowing for stakeholders across the healthcare ecosystem to better understand the disease. The HS dataset breaks down electronic medical record demographical data including geography, comorbidities, treatments, and provider specialty, and amplifies it with unstructured data from medical claims and physician notes of disease stage, anatomic location, and disease manifestation.

To learn more about OM1’s growing data networks, please email [e-mail].

About OM1

With specialization in chronic conditions, OM1 is re-imagining real-world evidence and insights by developing large electronically connected networks of clinicians and health data in dermatology, rheumatology, gastroenterology, cardiology, metabolism, respiratory, mental health, neurology and other specialty areas. Leveraging its data automation platform, OM1 Aspen, extensive clinical networks and artificial intelligence (AI) platform, PhenOM™, OM1 offers industry-leading enriched healthcare datasets, retrospective and prospective studies, advanced analytics, and AI-driven guidelines adherence and decision-support around diagnosis, risk management, and treatment. With a focus on high-quality data and clinical outcomes, the offerings are used for accelerating research, demonstrating treatment effectiveness, supporting regulatory submissions, monitoring safety, and informing commercialization.